SNSE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNSE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sensei Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.44 Mil. Sensei Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.77 Mil. Sensei Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $64.90 Mil. Sensei Biotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.10.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sensei Biotherapeutics's Debt-to-Equity or its related term are showing as below:
During the past 6 years, the highest Debt-to-Equity Ratio of Sensei Biotherapeutics was 0.10. The lowest was -0.23. And the median was 0.00.
The historical data trend for Sensei Biotherapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensei Biotherapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Debt-to-Equity | Get a 7-Day Free Trial | -0.23 | -0.01 | 0.02 | 0.08 | 0.10 |
Sensei Biotherapeutics Quarterly Data | |||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.08 | 0.08 | 0.09 | 0.10 | 0.10 |
For the Biotechnology subindustry, Sensei Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sensei Biotherapeutics's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Sensei Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (2.439 | + | 3.769) | / | 64.895 | |
= | 0.10 |
Sensei Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (2.439 | + | 3.769) | / | 64.895 | |
= | 0.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensei Biotherapeutics (NAS:SNSE) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Sensei Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephanie Krebs | officer: Chief Business Officer | C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850 |
John Celebi | director, officer: President & CEO | SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850 |
James Peyer | director, 10 percent owner | C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850 |
Cambrian Biopharma Inc | 10 percent owner, other: See Remarks | 228 PARK AVENUE S., #66643, NEW YORK NY 10003 |
Apeiron Investment Group Ltd. | 10 percent owner | BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
Presight Sensei Co-invest Fund, L.p. | other: See Explanation of Responses | 340 S. LEMON AVE., # 3391, WALNUT CA 91789 |
Van Der Horst Edward | officer: Chief Scientific Officer | C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210 |
Presight Co-invest Management, L.l.c. | 10 percent owner | 340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789 |
Christian Angermayer | 10 percent owner | BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
Patrick Stephen Gallagher | officer: Chief Business Officer | 66 HAROLD ST, BOSTON MA 02119 |
William R Ringo | director | |
Thomas G Ricks | director | H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625 |
Robert Hamilton Pierce | officer: Chief Scientific Officer | C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850 |
Kristian Humer | director | C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
Jessie English | director | C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850 |
From GuruFocus
By sperokesalga sperokesalga • 02-21-2023
By sperokesalga sperokesalga • 02-14-2023
By Marketwired • 11-01-2023
By Stock market mentor Stock market mentor • 02-06-2023
By sperokesalga sperokesalga • 04-20-2023
By Marketwired • 10-23-2023
By Value_Insider Value_Insider • 12-08-2022
By Marketwired • 11-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.